CRISPR & Gene Editing Design
Intellia Therapeutics
by Intellia Therapeutics, Inc.
In vivo CRISPR gene editing delivered systemically to treat genetic diseases at their root cause
Category
CRISPR & Gene Editing Design
Founded
2014
Headquarters
Cambridge, MA, USA
Overview
Intellia Therapeutics is developing CRISPR/Cas9-based therapies for the curative treatment of severe genetic diseases, with a primary focus on in vivo gene editing — directly editing genes inside the patient's body using lipid nanoparticle (LNP) delivery without removing cells for ex vivo manipulation. The company's lead program, NTLA-2001, targets transthyretin (ATTR) amyloidosis via a single-dose in vivo CRISPR edit of the TTR gene in the liver, with clinical data demonstrating up to 93% durable reduction in pathogenic TTR protein. Intellia's in vivo pipeline also includes treatments for hereditary angioedema (NTLA-2002) and alpha-1 antitrypsin deficiency, while its ex vivo platform targets acute myeloid leukemia and multiple myeloma with allogeneic CAR-T cell therapies. The company's LNP delivery technology enables efficient hepatic delivery of CRISPR components, and ongoing work extends to extrahepatic tissues including the lung and central nervous system. Intellia's core differentiation is its foundational licensing position on Cas9 intellectual property from the Broad Institute, combined with proprietary LNP delivery systems co-developed with Alnylam Pharmaceuticals. This gives the company both the editing machinery and the delivery infrastructure needed for effective in vivo editing. Clinical proof-of-concept showing durable multi-year responses from a single dose in a progressive genetic disease positions Intellia at the frontier of one-time curative medicine.
Key Features
Pre-Validated Guide Libraries
Genome-wide guide RNA libraries for common model organisms ready for experimental use.
Multiplexed Editing Design
Design multi-guide strategies for simultaneous editing at multiple genomic loci.
HDR Template Design
Optimized homology-directed repair template design for precise sequence insertions.
Editing Efficiency Prediction
ML models predict editing efficiency for specific guide-target combinations across cell types.
Regulatory Documentation
Automated generation of regulatory-ready documentation packages for gene therapy IND applications.
Pros & Cons
Pros
- +Multi-editor support covers CRISPR-Cas9, Cas12, base editing, and prime editing systems
- +Comprehensive off-target prediction algorithms evaluate billions of potential cleavage sites
- +AI-optimized guide RNA design maximizes on-target efficiency while minimizing off-target effects
- +Regulatory-ready documentation packages support IND applications for gene therapy programs
- +Integration with delivery system optimization (viral vectors, LNPs, electroporation)
- +Pre-validated guide libraries for common model organisms accelerate experimental design
Cons
- −Intellectual property landscape for CRISPR technology is complex with multiple competing patents
- −Delivery challenges limit efficient CRISPR component delivery to many tissue types in vivo
- −Off-target editing effects remain a safety concern especially for therapeutic applications
- −Regulatory pathways for gene-edited therapies are evolving and differ across jurisdictions
- −Editing efficiency varies significantly across cell types and genomic loci
Use Cases
Research Workflow Optimization
AI-powered optimization of research workflows to accelerate discovery timelines and improve reproducibility.
Data Analysis & Insights
Machine learning analysis of complex biological datasets to extract actionable insights and identify patterns.
Collaboration & Knowledge Management
Platform-enabled collaboration across distributed research teams with integrated data sharing and knowledge capture.